MR associations of the TYK2 loss-of-function variant with hypothyroidism, inflammatory bowel disease, primary biliary cirrhosis, and type 1 diabetes supported further investigation of TYK2 inhibitors as a potential treatment for these diseases in future clinical trials. This evidence concerns the gene TYK2 and inflammatory bowel disease.